SOLY Soliton, Inc. NASDAQ $22.58 on 17 Mar 2026: Oversold bounce may spark short rebound

SOLY stock closed at $22.58 on 17 Mar 2026 after heavy intraday trading, giving a clear oversold bounce setup for short-term traders. Volume hit 1,347,169 shares versus an average of 182,838, a relative volume of 7.37, suggesting forced liquidations or short covering. On the NASDAQ in the United States, Soliton, Inc. shows price above its 50-day average $20.88 and 200-day average $20.64, supporting a rebound thesis. We assess fundamentals, technicals, and Meyka AI forecasts to frame a measured oversold-bounce trade idea for investors.

Why the SOLY stock bounce matters

Soliton, Inc. (SOLY) is trading on the NASDAQ in USD and sits near its 52-week high $22.60, after a big surge in volume. The volume spike to 1,347,169 shares signals short covering more than fresh long accumulation. For an oversold bounce strategy, price above both the 50-day $20.88 and 200-day $20.64 moving averages is a constructive technical trigger.

SOLY stock technical setup and risk signals

Technically, the stock opened at $22.56 and traded between $22.56 and $22.59 today. Keltner channels center at $22.58, showing compressed volatility. Average true range is $0.03, indicating tight intraday moves. High relative volume with narrow range can precede a quick repricing; traders should place tight risk controls given limited traditional trend oscillator data.

Fundamentals: valuation, liquidity, and margins for SOLY stock

Soliton operates in Healthcare, Medical – Devices. Financial ratios are mixed: current ratio 11.44, cash per share $1.50, and price-to-book 15.37. Earnings metrics show negative profitability with PE TTM -32.75, reflecting losses. Enterprise value to EBITDA is 2.24, and operating cash flow per share is -0.55. Strong liquidity cushions the firm, but high PB and negative earnings flag valuation and profitability risks.

Meyka AI grade and model forecast for SOLY stock

Meyka AI rates SOLY with a score out of 100: 66.33 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of $20.96 and a yearly target of $69.80. Versus the current $22.58, the yearly projection implies an upside of 209.10%. Forecasts are model-based projections and not guarantees.

Trading plan and sector context for SOLY stock

Soliton sits in Healthcare devices, where sector flows can be binary around regulatory news. For an oversold bounce trade we recommend: 1) a short-term entry near $22.50–$22.80, 2) a tight stop below $22.00, and 3) scaled profit targets at $25.00 and $30.00. Watch volume and any company or sector news that could invalidate the bounce thesis.

Catalysts, risks, and watch items for SOLY stock

Catalysts include fresh clinical updates, commercial rollouts, or M&A activity in medical devices. Key risks are continued negative earnings, high price-to-book, regulatory setbacks, and a thin institutional float that can amplify volatility. Monitor average volume 182,838 for normalization and any SEC filings or press releases from Soliton for confirmation.

Final Thoughts

Key takeaways on SOLY stock: the market closed the session at $22.58 on 17 Mar 2026 with unusually high volume 1,347,169, creating a classic oversold-bounce setup on the NASDAQ in the United States. Fundamentals show strong liquidity with current ratio 11.44 but negative profitability and a high price-to-book 15.37, so gains may be short lived without follow-through news. Meyka AI’s forecast model projects a yearly target of $69.80, an implied upside of 209.10% from today’s price, while the monthly model sits at $20.96. Meyka AI rates SOLY 66.33 (B, HOLD), reflecting mixed signals between technical momentum and fundamental risk. For traders, use tight stops and predefined targets: possible short-term exits at $25.00 and $30.00. Remember, forecasts are model-based projections and not guarantees. For investors, the trade-off is clear: a high-volatility bounce with meaningful upside scenarios but material execution and valuation risk. Our coverage uses Meyka AI as an AI-powered market analysis platform to quantify that balance.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.